Misuse of Drugs (Medicinal Cannabis) Amendment Bill

Size: px
Start display at page:

Download "Misuse of Drugs (Medicinal Cannabis) Amendment Bill"

Transcription

1 Misuse of Drugs (Medicinal Cannabis) Amendment Bill Departmental Report Prepared by the Ministry of Health 11 June

2 Contents Introduction... 3 Submissions... 3 Overview... 3 Section One - Key topics that are relevant to the Bill... 4 Exception and Statutory Defence (clause 5 of the Bill, amending section 7 of the Act)... 4 Quality standards (clause 7 of the Bill, amending section 14 of the Act)... 9 Cannabidiol Section Two - Key topics raised in submissions that are outside the scope of the Bill Details relating to the setting of quality standards Recreational use Affordability of products Industry opportunities Regulation of the industry A review of the Misuse of Drugs Act and penalties Implications for Health Care Professionals Summary of recommendations for change Appendix One Current context and the Scheme Current context The Scheme

3 Introduction 1. This report provides an overview of submissions made to the Health Select Committee on the Misuse of Drugs (Medicinal Cannabis) Amendment Bill (the Bill), and the Ministry of Health s recommendations on proposed changes to better reflect the intent of the Bill. 2. The Parliamentary Counsel Office has been consulted in the development of this report. 3. The Bill was introduced on 20 December 2017 and meets the Government s 100 day commitment to introduce legislation to improve access to medicinal cannabis. 4. The Bill is guided by the principles of fairness, quality and safety and compassion. 5. The Bill: introduces an exception and a statutory defence for terminally ill people to possess and use illicit cannabis and to possess a cannabis utensil provides a regulation-making power to enable the setting of standards that products manufactured, imported or supplied under licence must meet deschedule cannabidiol (CBD) so it is no longer a controlled drug. 6. The Bill supports the establishment of a Medicinal Cannabis Scheme (the Scheme) by allowing the setting of quality standards that all medicinal cannabis products must meet. The Scheme aims to improve access to quality medicinal cannabis products on prescription, including by enabling domestic cultivation and manufacture for commercial purposes. An overview of the current regime for accessing medicinal cannabis and the proposed establishment of the Scheme is provided in Appendix One. 7. This report is divided into two sections. Section one covers key topics that are relevant to the Bill. Section two covers key topics raised in submissions that are outside the scope of the Bill. 8. A summary of recommended changes is included on page 21. Submissions Overview 9. The Committee received written and supplementary written submissions. 10. There were 1539 submissions received from individuals and 72 from organisations including: 11 health care professional (HCP) bodies and medical associations 13 companies interested in being involved in the medicinal cannabis industry 48 other organisations such as patient support groups. 11. The Committee heard 158 oral submissions on 4, 11 and 30 April 2018 and 2, 3 and 9 May The majority of submissions (88 percent) support individuals being able to use cannabis for medicinal use, with only one percent of submitters (including three HCP bodies) not in support. 1 The actual number of submissions received was 1697 but after adjusting for blank submissions, duplicates and supplementary submissions (all submissions received from the same submitter were counted as one submission), 1611 submissions were received. 3

4 13. Of the 778 submissions that commented on the Bill, 27 percent (209 submissions) supported the Bill in its entirety, 6 percent (43 submissions) did not support the Bill at all, and the rest were unclear. Fifty-two percent of submitters (402 submissions) who commented on the Bill (including the majority of individuals who were against the Bill) indicated that it did not go far enough. Section One - Key topics that are relevant to the Bill Exception and Statutory Defence (clause 5 of the Bill, amending section 7 of the Act) 14. The exception and statutory defence provisions for terminally ill people to possess and use illicit cannabis is intended as a compassionate measure until affordable quality products are available under the Scheme. 15. The provision is limited to the terminally ill, recognising that the risks and benefits of using illicit cannabis with no quality controls and without medical oversight is different for this group of patients. 16. The provision is not intended to encourage terminally ill people to use illicit cannabis. 17. Thirty-five percent of all submitters (571 submissions) commented on the exception and statutory defence provision. Of those 571 submissions: 33 percent (186 submissions) supported the provision four percent (25 submissions) (including three HCP bodies and two other organisations) were against the provision 63 percent (360 submissions) were unclear. 18. The majority of submitters that commented on the provision, regardless of whether they supported the provision or not, indicated that the provision does not go far enough. Suggestions for broadening the scope focussed heavily on providing protection for individuals suffering from other illnesses and to a lesser extent on enabling supply to, and self-cultivation by, those covered by the exception and statutory defence. Other reasons for not supporting the provision were: protection for owners of premises such as Hospices further protections for the terminally ill the need for good quality products problems with the definition or diagnosis of a terminal illness inadequate protections for individuals in possession of utensils concerns that the legislation is not well designed. Extending the exception and statutory defence to chronic pain and other conditions 19. Many submitters commented that the exception and statutory defence should be extended to more conditions. Of the 571 submissions that commented on the provision, the most commonly suggested conditions that the provision should be extended to were: pain, including chronic pain (174 submissions) severe and debilitating illness (44 submissions) cancer (22 submissions) epilepsy (16 submissions) multiple sclerosis (17 submitters). 4

5 20. In addition, 74 submissions that commented on the provision stated that anyone with a doctor s endorsement should be allowed to access illicit cannabis without fear of prosecution. 21. The exception and statutory defence provision is a compassionate response to the reality that some terminally ill people are using illicit cannabis, and are worried about potential criminal charges. The provision is limited to the terminally ill, recognising that the lack of efficacy data, and consideration of the risks and benefits of using illicit cannabis with no quality controls and without medical oversight, is different for this group of patients. 22. The Ministry considers that any other group of patients, such as those with chronic pain, should continue to be able to access quality medicinal cannabis products on prescription. The risk-benefit ratio for patients with other conditions is different to those who are terminally ill, as unlike the terminally ill, they may have many years of life ahead of them. 23. It is appropriate that people with other conditions, including chronic pain, receive medical advice about the use of medicinal cannabis products, including potential interactions with other medications and medical conditions. People with chronic pain, or other conditions, can be prescribed a medicinal cannabis product under the current legal pathway, if their medical practitioner supports its use for that individual. 24. Extending the provision to other conditions may also risk undermining the intent of the Scheme which is to improve access to quality medicinal cannabis products on prescription. 25. The Ministry does not recommend extending the exception and statutory defence provision to include people who are diagnosed with other conditions. Extending the exception and statutory defence provision to supply and cultivation 26. Of the 571 submissions that commented on the exception and statutory defence, submitters recommended the provision be extended to: growers (93 submissions) suppliers (such as green fairies who can also be growers) (172 submissions) friends and whānau (231 submissions) caregivers (130 submissions) nominated people (4 submissions) Less than one percent of submitters supported the terminally ill being able to grow cannabis for their own medicinal use. 28. Several submitters indicated that the Bill needed to establish a supply route. 29. Under the Act, a person who transports a controlled drug to a person who can possess it legally is not committing an offence. This provision could be used as a defence for people transporting cannabis to terminally ill people, as they will be able to possess it legally. 30. The defence provided by the Act would not protect the person against a charge of procuring the drug from a supplier. 31. Although we acknowledge that terminally ill people may rely on friends, whānau, and carers to source illicit cannabis for them, we do not recommend extending the provision to cover cultivation and supply. 32. The Office of the Clerk provided advice to the Health Committee that it is outside the scope of the Bill to extend the exception and statutory defence from possession and use to include 2 A number of submitters made more than one suggestion. 5

6 cultivation. This advice was provided on the basis that the Act treats cultivation very differently to possession and use and because the Bill s explanatory material clearly focuses on possession and use only. 33. Supply of a controlled drug is also a very different offence to possession or use and carries a much higher penalty. The Ministry understands that extending the exception and statutory defence provision to protect suppliers is also likely to be outside the scope of the Bill on the basis of the advice provided by the Office of the Clerk. 34. The provision is intended as a compassionate measure until the Scheme is established and should remain as an exception for extraordinary circumstances. 35. The Scheme is intended to enable the commercial supply of domestically produced medicinal cannabis products and will regulate all steps of production and supply through a licensing framework. 36. The Ministry does not recommend extending the exception and statutory defence provision to supply and cultivation. Protection for owners of premises (such as Hospices) 37. Several submitters raised concerns that owners of premises (such as Hospices) would be committing an offence under section 12 of the Act by letting individuals consume illicit cannabis on the premises. 38. A person who has a certificate stating that they have a terminal illness and possesses or uses cannabis will not be committing an offence under the Act. A person with a terminal illness who brings product onto a premises is not committing an offence and therefore the premises owner would not be committing an offence if they knew the person was using illicit cannabis. 39. The premises owner would only be committing an offence if they knew that a person was supplying cannabis to a terminally ill person, as that would remain an offence under the Bill. Just as we do not recommend changes to the Bill to protect individuals who are supplying the terminally ill with illicit cannabis, we do not recommend changes to the Bill to protect premises owners who are aware that individuals are supplying the terminally ill with illicit cannabis on their premises. 40. The Ministry does not recommend any changes to the Bill to protect owners of premises where illicit cannabis is used by the terminally ill because the premises owners are not committing an offence. Further protections for the terminally ill 41. Submitters were concerned about the risk that associating with drug dealers would pose to individuals accessing illicit product. 42. A number of submitters recommended that the terminally ill should be completely protected from the prospect of arrest and court appearances. 43. The Ministry acknowledges the risks associated with sourcing illegal product. The provisions are not intended to encourage terminally ill people to use illicit cannabis. 44. The Ministry will continue to work with enforcement agencies to ensure that the provision is implemented in line with the Bill s principles of fairness, quality and safety and compassion. 45. The Ministry does not recommend any changes to the Bill in response to these submissions. 6

7 The definition of terminal illness (clause 4 of the Bill to amend section 2 of the Act) 46. Of the 3 percent of submissions (54 submitters) that commented on the definition of terminally ill: two submitters agreed with the definition 29 submitters disagreed with the definition 23 submitters were unclear. 47. The key themes raised were that: the person may live longer than a year after the diagnosis of a terminal illness. Submitters asked what the process is if the person lived longer than a year, and if they can still access medicinal cannabis it is difficult to predict when a person has a year to live. Medical associations and several others raised concerns that terminal illness is difficult to define, as it is not a medical condition the time period should be extended. 48. The definition of terminally ill is consistent with the New Zealand Palliative Care Strategy which states that palliative care should generally be available to people whose death from progressive disease is likely within 12 months. While the Ministry acknowledges that it can be difficult to accurately predict how long a person has left to live, doctors already provide their expert opinion on the matter for life insurance and other purposes. 49. The Ministry intends to provide guidance to the public and health practitioners on implementing this provision. 50. The Ministry does not recommend any changes to the definition of terminal illness. The diagnosis of terminally ill 51. The Royal Australasian College of Physicians recommended that nurse practitioners should not be allowed to diagnose a terminal illness because it is not part of their training or expected curriculum. 52. Nurse practitioners are qualified to diagnose conditions under their scope of practice that are within their area of expertise. Some nurse practitioners work specifically in the areas of palliative and aged care. 53. The Ministry does not recommend any changes to the Bill as a result. The terminally ill need good quality products 54. Several submitters considered either that quality product should be provided to terminally ill people, or that individuals should only be able to access quality product. 55. Many health care practitioners and medical associations were concerned about the exception and statutory defence provision because they consider that medicinal cannabis products should be regulated in the same way as other medicines. 56. Submitters raised concerns that the use of medicinal cannabis products could be harmful without medical oversight. 57. A number of submitters felt that the terminally ill are vulnerable and should not receive a lesser standard of care than other population groups. 7

8 58. A number of submitters were concerned about the exception and statutory defence provision because they consider that there is not enough evidence to support the use of medicinal cannabis. 59. The Ministry agrees that it is important that people have access to quality products, which is why the Bill provides for the setting of quality standards. 60. The Ministry considers that it is appropriate that all individuals, including the terminally ill, receive medical advice about the use of medicinal cannabis products. The Ministry strongly encourages all individuals to seek medical advice when considering the use of licit or illicit cannabis for medical reasons. 61. The exception and statutory defence is limited to the terminally ill, recognising that the significance of a lack of efficacy data, and consideration of the risks and benefits of using illicit cannabis with no quality controls and without medical oversight, is different for this group of patients. 62. The provision is intended as an interim, compassionate, measure until the Scheme is established, and quality product is supplied. 63. The Ministry does not recommend any changes to the Bill to remove the exception and statutory defence provisions. Exception provision for cannabis utensils (clause 6 of the Bill to amend section 13 of the Act) 64. The Royal Australasian College of Physicians was also concerned that the Bill currently provides an exception and statutory defence for the possession and use of illicit cannabis but only provides a defence for possession of cannabis utensils. 65. It is an offence to possess a drug utensil for the purpose of using an illicit controlled drug. Since a terminally ill person who has a certificate is not committing an offence by possessing or using illicit cannabis, it is also not an offence for that person to be in possession of a utensil. 66. The exception provision in the Bill therefore already protects the terminally ill against the offence of being in possession of a utensil and no changes to the Bill are needed or recommended as a result. Design of the exception and statutory defence provision 67. The Legislation Design and Advisory Committee raised concerns that the exception and statutory defence does not comply with the Legislation Advisory Committee Guidelines 3. This is because the provision relies on the non-enforcement of prohibitions that already exist in the Act against the supply and cultivation of cannabis so that a terminally ill individual can source product. As a result, the Committee recommended that the provision not proceed until a scheme for regulating the legal production and supply of medicinal cannabis is ready to be enacted. 3 The Legislation Advisory Committee Guidelines provides guidance to determine if legislation is well designed and consistent with legal and constitutional principles. 8

9 68. If the provision is retained, the Legislation Design and Advisory Committee suggested that the exception be moved to section 8 of the Act to be consistent with how other exceptions are treated. 69. The provision is not intended to encourage the use of illicit cannabis, rather it acknowledges that some terminally ill people choose to self-medicate with illicit cannabis that is not prescribed. The provision is intended as an interim, compassionate, measure until the Scheme is established, and quality product is supplied. For these reasons, the Ministry does not consider there is a need to remove this provision. 70. Moving the exception to section 8 of the Act has no effect on policy but the Ministry agrees that it makes the Act easier to navigate and understand. Recommendation I: The Ministry recommends the exception for the terminally ill to be able to possess and use cannabis be moved to section 8 of the Act. Quality standards (clause 7 of the Bill, amending section 14 of the Act) 71. The Bill supports the Scheme by allowing the setting of quality standards that all medicinal cannabis products must meet. The Scheme aims to improve access to quality medicinal cannabis products on prescription. Further detail of the Scheme is provided in Appendix One. 72. Thirty percent of all submissions (476 submitters) commented on the regulation making provision in the Bill. This provision will enable the Ministry to require all medicinal cannabis products manufactured, imported or supplied under a licence granted under the Act to meet quality standards. The majority of submitters (1135) did not comment on this provision of the Bill. 73. Of the 476 submissions that commented on the provision: 95 percent supported the provision 0.5 percent did not support the provision 4.5 percent were unclear. 74. Key themes identified were: minimum standards should be well regulated products should be able to be advertised. Products should be well regulated 75. A number of submitters commented that products need to be well regulated to ensure public safety, that the content should be known and that there should be confidence in prescribing and using the product. Several submitters supported a legislative rather than voluntary approach to products meeting standards. 76. The Ministry agrees that standards need to be compulsory and enforced. The mechanism will be enabled through clause 7 of the Bill which allows for the setting of minimum quality standards which all products or classes of products must meet. Enforcement of the standards is part of the Scheme and outside the scope of the Bill. 77. The Ministry does not recommend any changes to the Bill. 9

10 Extending the setting of quality standards to include cultivation and manufacture 78. Currently, clause 7 of the Bill only allows the setting of quality standards that all products that are manufactured, imported or supplied under a licence granted under the Act must meet. The Ministry considers that the provision needs to be broadened to include regulations to be made regarding minimum standards for all stages of cultivation, production and manufacture (see Recommendation II). 79. Without the ability to set these additional standards, there is a risk that the Scheme will not be able to ensure products are consistently of an acceptable quality and can be prescribed with confidence. The process for setting quality standards 80. Because of their highly technical nature, the Ministry considers that it would be more appropriate for the technical details of quality standards to be published by the Director- General of Health. This will give the regulator the ability to respond to changes in technology, an evolving safety profile and keep pace with an emerging industry. 81. This is particularly important for medicinal cannabis because the industry is still quite new and international standards and regulation are still developing. This amendment will help the right regulatory balance to be found more quickly. 82. The Ministry intends to consult publicly before setting or making any changes to quality standards. The proposed change is not dissimilar to how quality standards are currently made and amended for medicines. Recommendation II: The Ministry recommends that clause 7 of the Bill (to amend Section 14 of the Act) is amended to allow regulations to prescribe standards for all stages of cultivation, production and manufacture, and criteria for when the regulations will apply. The technical detail of the standards will be published by the Director-General of Health. Making information about products that meet the quality standards available 83. Several submitters raised concerns that medicinal cannabis products will not be able to be advertised so people will not know what is available and the industry will find it difficult to establish themselves in the market and make their investment viable. 84. In addition to being regulated under the Act, medicinal cannabis products used for a therapeutic purpose are also regulated under the Medicines Act The Medicines Act allows medicines that have not received consent for distribution from Medsafe 4 to be prescribed, but does not allow them to be advertised. This is because the safety, efficacy, and quality of the products has not been assessed, so they should not be widely available. 85. The Scheme will mitigate some of these concerns by ensuring that products meet a minimum quality standard. It is unlikely that the Scheme can achieve its objective of improving access to quality medicinal cannabis products if doctors have no way of knowing which products meet the quality standards and how to access them. 4 Medsafe is the New Zealand medicines regulator and sits within the Ministry of Health 10

11 86. Regulations can be made under section 37(1)(o) of the Act to regulate the advertising of medicinal cannabis products that meet the quality standards. 87. The Ministry recommends that the Bill is further amended to explicitly provide that regulations made under section 37(1)(o) of the Misuse of Drugs Act are intended to override the provisions of section 20 of the Medicines Act 5. The Ministry recommends the new clause allows the making of regulations enabling the provision of information about the availability of medicinal cannabis products to appropriate health professionals. 88. The details of what should be advertised are yet to be worked through. 89. The details of who advertising of controlled drugs should be restricted to are yet to be worked through but is likely that they will be at least as restrictive as regulation 50 of the Misuse of Drugs Regulations 1977, which restricts advertising of controlled drugs to practitioners and pharmacists. 90. The Ministry does not recommend broadening the advertising provisions further because that would be likely to undermine the medicines framework. 91. The Ministry acknowledges that enabling regulations to override the prohibition in section 20(2)(c) of the Medicines Act should only be done where: there is a strong need or benefit to do so the empowering provision is as limited as possible to achieve the objective, and there are safeguards to reflect the significance of the power. 92. The Ministry is satisfied that these requirements are met as the regulations will only allow the most limited advertising necessary to enable the Scheme. Enabling such provision of information is essential to ensuring the scheme can function but the information should be limited to the smallest possible audience. Recommendation III: The Ministry recommends that a new clause is added to amend the Act to make it clear that regulations made under section 37(1)(o) are intended to override section 20 of the Medicines Act by allowing regulations enabling the provision of information about the availability of medicinal cannabis products to appropriate health professionals. Cannabidiol 93. Removing CBD and CBD products from being captured under the Act is required in order to regulate these products in line with their risk profile. 94. Twenty-three percent of submissions (369 submitters) commented on the cannabidiol (CBD) provision. Of these: 81 percent supported removing CBD from the Act two percent opposed removing CBD from the Act 17 percent were unclear. 95. Of the 369 submitters who commented on the provisions, 49 percent felt that the provision did not go far enough, regardless of whether they supported the provision or not. 96. The key themes identified were: concerns with the appropriateness or necessity of removing CBD from the Act the benefits of CBD the definition of CBD product 5 Section 109 of the Medicines Act already provides that where the two Acts are inconsistent, the provision of the Misuse of Drugs Act prevail. 11

12 removing other cannabinoids from the Act. Descheduling of CBD 97. A number of submitters noted that they do not believe CBD is an isomer 6 of THC One submission from an HCP body stated that there is insufficient evidence of the efficacy of CBD to justify removing it from the Act. A further submitter commented that a full risk assessment of CBD should be undertaken before it is removed from the Act. There were 114 individuals who submitted the same or a substantially similar submission (known as a form submission). The form submission noted that CBD should be treated the same as other non- THC cannabinoids (in other words it should not be a controlled drug). 99. The Ministry s position is that CBD is captured under the Act as an isomer of THC The Expert Advisory Committee on Drugs (EACD) advises the Minister of Health on drug classification matters. Based on its assessment of CBD's risk profile, lack of psychoactive properties and potential therapeutic value, the EACD advised that it would support a decision by the Minister to deschedule CBD from the Misuse of Drugs Act The Ministry considers that CBD should not continue to be captured under the Act The Ministry does not recommend any changes to the Bill in response to these submissions. Benefits of CBD 103. A number of submitters noted that CBD has health benefits and therapeutic value. Of the 369 submissions that commented on the CBD provision, four percent (13 submitters) felt that CBD is an effective treatment for pain. Submitters also commented that CBD could be an effective treatment for inflammation (one submitter), cancer (one submitter), anxiety (one submitter), neuropathy (one submitter), fibromyalgia (one submitter), and Parkinson s disease (one submitter) Of the 369 submissions that commented on the CBD provision, two percent recommended that CBD be more available (five submitters recommended that CBD should be available over the counter, and one submitter recommended that CBD should be available on prescription) The Ministry agrees that CBD has potential therapeutic value and has no or little psychoactive effect, and supports the removal of CBD from the Act CBD is also scheduled as a prescription medicine under the Medicines Act If CBD is removed from the Act, the Ministry intends to refer CBD to the Medicines Classification Committee 8 to consider whether the prescription medicine status of CBD remains appropriate The Ministry does not recommend any changes to the Bill to make CBD or CBD products more readily available. 6 Substances are isomers of each other when they contain the same number and type of atoms (eg tetrahydrocannabinol and CBD both have 21 carbon atoms, 30 hydrogen atoms and two carbon atoms) but the atoms are arranged in a different order. In other words the substances look different even though they are made up of the exact same building blocks. 7 THC refers to 9-tetrahydrocannabinol which is the main psychoactive component found in cannabis. 8 The Medicines Classification Committee makes recommendations to the Ministry (as the delegate of the Minister of Health) on the classification of medicines under the Medicines Act

13 Status of other cannabinoids under the Act 108. Eleven submitters recommended that other non-psychoactive cannabinoids should not be captured by the Act on the basis that they believe these cannabinoids are or could be of therapeutic benefit and there is no risk associated with them The Act currently schedules tetrahydrocannabinols (THCs 9 ) as controlled drugs because these are specifically listed in the Act. The Act does not capture other cannabinoids in general because they are not specifically listed in the Act. No changes are required to remove all cannabinoids (such as cannabigerol, which is found in cannabis) in general from the Act However, the Act then has provisions to capture a number of substances that have similar structures to those specifically listed in the Act or that can be easily converted to the substances listed in the Act. These provisions are referred to as the related substances provisions A number of cannabinoids (such as CBD and cannabichromene, which are both found in cannabis) will be captured under the Act as substances that are related to THCs A number of these substances that are captured as substances related to THCs will have little to no psychoactivity and many have potential therapeutic benefits (such as CBD). The Ministry understands that at least one other cannabinoid with little to no psychoactivity is currently being investigated for therapeutic use The Ministry considers that it is reasonable that substances that are related to THCs should not be captured under the Act where there is evidence that the substances have little or no psychoactivity. Recommendation IV: The Ministry recommends revising the Bill so that substances related to tetrahydrocannabinols that are naturally found in cannabis are no longer captured under the Act where there is evidence that they have little to no psychoactivity. Definition of CBD product (clause 4 of the Bill, amending section 2 of the Act) 114. The Bill currently allows not more than two percent of the total cannabinoid content of CBD products to consist of other cannabinoids usually found in cannabis Of the 369 submissions that commented on the CBD provision: less than one percent (three submitters) suggested that the two percent allowance in CBD products of other cannabinoids should be replaced with a two percent allowance of THC two percent (nine submitters) recommended that the definition of CBD product should be changed to increase the THC content on the basis that it is likely to be more effective less than one percent (two submitters) suggested not restricting THC content at all The Act currently schedules THCs as controlled drugs but not other cannabinoids. Most cannabinoids have little to no psychoactivity (eg CBD, cannabichromene and cannabigerol) unless they are also THCs. 9 THCs are a family of largely psychoactive substances that share similar structures and are a subset of the cannabinoid family of substances. 13

14 117. The Ministry recommends that the two percent allowance in CBD products should only apply to THCs and their psychoactive related substances that are naturally found in cannabis, as this is in line with how cannabis preparations are treated under the Act (see point 118) The change means that the amount of cannabinoids in CBD products will not be restricted unless they are also THCs In other words, a much smaller set of substances will be controlled in CBD products than the provision originally proposed. Recommendation V: The Ministry recommends revising the definition of CBD product (clause 4 of the Bill) to allow not more than two percent of the total CBD, THCs and related psychoactive substances content to consist of THCs and related psychoactive substances that are naturally found in cannabis There is no single internationally accepted allowance of other cannabinoids in CBD products. In Australia, the allowance is two percent. In the United States of America, some States specify an allowable THC level in CBD products. Levels range from zero point three percent to eight percent The two percent allowance was proposed to reduce barriers to accessing CBD products (because it is difficult to obtain a pure product from cannabis) and align with Australia. The EACD does not consider an impurity level of up to two percent of other cannabinoids to be clinically significant 122. Products containing CBD and more than two percent psychoactive tetrahydrocannabinols will still be available on prescription but will be subject to the requirements of the Act The Ministry does not recommend any further changes to the definition of CBD product to alter the two percent allowance. Two percent allowance for other non-psychoactive substances found in cannabis 124. The form submissions received from 114 individuals also commented that medicinal cannabis products should be controlled by the level of THC they contain, not other non-psychoactive cannabinoids The Ministry recommends in Recommendation IV that non-psychoactive substances that are naturally found in cannabis and that are captured under the Act as substances related to THCs, should no longer be captured under the Act The Ministry acknowledges it is difficult to isolate a pure substance from cannabis, but considers that the question of whether an allowance for contaminants should be permitted in substances other than CBD should be considered by the EACD The Ministry does not consider that a two percent allowance of THCs and psychoactiverelated substances that are naturally found in cannabis should be applied to the substances described in recommendation IV Products containing substances related to THCs, with little to no psychoactivity, that are naturally found in cannabis and any THCs or psychoactive-related substances that are

15 naturally found in cannabis will still be available on prescription. However, these products will be subject to the requirements of the Act. Section Two - Key topics raised in submissions that are outside the scope of the Bill Details relating to the setting of quality standards 129. A number of submitters felt that we should review and adopt overseas quality standards One submitter suggested that an independent commission for the development of the industry be established with public consultation on all requirements Several submitters commented that they wanted public consultation on the standards and/or that the standards should be specified in the Bill Of the 476 submissions that commented on the quality standards, 109 commented on the type of quality standards that medicinal cannabis products should meet. Of these 109 submissions: 49 stated the standards should identify the composition of cannabinoids in a product 33 stated products should meet medicine standards 10 wanted a range or mix of grades including pharmaceutical 14 stated standards should be food or herbal or organic grade or a mix of these 3 had other suggestions Approximately one quarter of submitters who commented on the quality standards provision stated that the level of THC in a product should be controlled Two submitters opposed product testing, with one submitter concerned that rigorous testing would unnecessarily delay the availability of products and increase their price Regular testing or testing of products before sale was recommended by 161 submitters. There was concern that composition and contaminants should be known. Some noted the need for labelling of THC and CBD levels. About a quarter of these submitters noted the need for testing to be by an approved/accredited laboratory Several submitters commented that the process from planting to manufacture should be controlled Several submitters commented that standards should be similar to Canada s Good Production Practices. Several submitters commented that product should be pesticide-free and organic, while another commented that products should be safe and sterile. Several submitters commented that they wanted simple or whole plant preparations rather than highly processed and expensive pharmaceuticals A third of submitters stated that there should be regular testing of products to verify composition and contaminant levels The Ministry is currently reviewing the standards that apply in other jurisdictions. The process for setting or making changes to quality standards will follow a robust process that will include the opportunity for public comment. 15

16 140. A product with high levels of THC may be clinically indicated for a particular patient and/or may be administered at a low dosage level. The key concern around product quality is that the composition is as stated so that dosage can be accurately calculated and that contaminant levels are safe. As such, the Ministry does not recommend restricting the level of THC in medicinal cannabis products in general In line with how other medicines are treated, quality standards are necessary to reduce the risk to the public that product is poorly grown or manufactured, and as a result, for example, contains harmful pesticides and heavy metals The development and setting of quality standards is outside the scope of the Bill. Work on the quality standards is ongoing, but will take account of international practices and the Ministry s experience in dealing with similar products. The Ministry intends to publicly consult on the quality standards As part of the development of the quality standards, compliance and monitoring requirements, the Ministry will give careful consideration to when, and how often, products will need to be tested. Recreational use 144. Twenty-nine percent of the submissions mentioned recreational use, and the large majority of these submissions supported the legalisation or decriminalisation of cannabis for recreational use Legalisation or decriminalisation of cannabis for recreational use is outside the scope of the Bill, but will be the subject of a referendum to be held by Affordability of products 146. A number of submitters commented that products need to be affordable, with several submitters concerned that pharmaceutical grade products will be too expensive A number of submitters suggested that we could ensure products are affordable by accepting herbal or food grade standards, rather than requiring products to meet pharmaceutical standards Ten percent of submissions mentioned concerns about the cost of accessing products. Sixtysix percent of those submissions (including one submission from a HCP body, two submissions from industry and nine submissions from other organisations) asked for the Bill to ensure products are reasonably priced or specifically recommended that products be subsidised The Ministry acknowledges the demand for affordable products and will take this into consideration when developing the regulatory framework, and setting the quality standards. However, as with regulation of any good or service, the Ministry s primary focus will be on ensuring that regulation is risk proportionate Subsidising products is outside the scope of the Bill Industry has indicated that they expect to be able to produce quality products in New Zealand for significantly less than the current cost of imported products. One company has indicated they expect to be able to produce product in New Zealand at or near the current black market prices. The price of domestically-produced product will be affected by the requirements of the 16

17 Scheme, including the cost of compliance in New Zealand, and this will be carefully considered when establishing the quality standards and the regulatory scheme. Industry opportunities 152. Numerous submitters from the public, industry and other organisations commented that enabling a domestic market would create jobs, drive economic growth and support regional development. Ways to support the industry 153. Two percent of submitters (eighteen from the public, three from industry, four other organisations) recommended that financial support should be provided to help the industry develop Several submitters suggested that the Scheme should enable a cottage industry Financial support for the industry is outside the scope of the Bill. The Ministry will consider ways to minimise costs to industry when establishing the Scheme and make the requirements of the Scheme workable for all of industry (big or small). However, as with regulation of any good or service, the Ministry s primary focus will be on ensuring that regulation is risk proportionate. Not-for-profit model 156. Several organisations (and numerous supporters of those organisations) suggested that the industry should only consist of licensed not-for-profit organisations such as community trusts, in a similar way to how gambling is regulated in New Zealand Setting up a not-for-profit model would require legislative change, but is outside the scope of the Bill because the Bill does not establish the licensing framework. Regulation of the industry 158. Twenty percent of submitters commented that they supported regulation of the medicinal cannabis industry in some form. All industry individuals or bodies were in favour of regulation of some sort Suggestions ranged from controlling just the sale of seed or licensing individuals to grow their own to licensing commercial growers and dispensaries and issuing users with a medical card to be able to access products. A number of submissions referred to the models used in Canada and various states of North America as good examples of regulatory frameworks Under the Misuse of Drugs Act, almost all activities involving controlled drugs must be carried out under a licence issued by the Ministry of Health. This framework is necessary to support access to controlled drugs for medicinal use while reducing the likelihood of diversion and for New Zealand to meet its international obligations under the United Nations Conventions. Utilising the framework that is already in use is also expected to be more efficient than 11 A cottage industry is a business or manufacturing activity carried out in people s homes. 17

18 implementing a new framework, which will deliver savings to industry and the public and make it less complicated for industry Other jurisdictions have implemented comprehensive medicinal cannabis schemes. The Ministry will look to learn from the experiences of other jurisdictions and incorporate relevant and reasonable initiatives at an operational level to simplify and strengthen the medicinal cannabis scheme. Regulating in line with the alcohol model 162. A number of submissions recommended regulation of medicinal cannabis should be similar to regulation of alcohol This is more in line with recreational use and is not suitable for a medical model, particularly given that the main constituents of medical interest in cannabis (THC and CBD) are both prescription medicines at this time and THC will continue to be a controlled drug. This suggestion would also require legislative change that is outside the scope of the Bill. Age restrictions 164. A small number of submissions suggested an age restriction ranging from 18 to The risks associated with use by individuals under the age of 18 will be appropriately managed under the Scheme, as products will only be accessible with clinical oversight or when the individual is terminally ill (as the risk-benefit analysis for the terminally ill differs from other patient groups). Clinical trials are currently under way to investigate the use of cannabis-based products for the treatment of childhood conditions (eg Dravet syndrome, a severe form of childhood epilepsy) and these studies will help inform safe prescribing practice. An age restriction for medical use is not recommended. Use of taxes to subsidise products or pay for education and treatment 166. A number of submissions commented on the benefits to New Zealand of having a regulated industry paying tax, such as the ability to use these funds to subsidise products for those in need, or contribute to education and treatment services Education and treatment services would largely be in response to illicit use and it is not appropriate for the legitimate medicinal cannabis industry to be funding these services. Using taxes from the industry to subsidise products is also likely to increase the cost of products to individuals which goes against the Government s aim of improving access to these products. Enabling export 168. Fourteen percent of submissions supported an export market for medicinal cannabis products or requested that the Bill be amended to explicitly allow export The Ministry s position is that the Act and associated regulations already allow export of controlled drugs (including medicinal cannabis products) under a license issued by the 18

19 Ministry of Health. The Ministry does not recommend changes to the Bill to explicitly allow export The Bill allows for the setting of quality standards that all products that are manufactured, imported or supplied must meet. The Ministry does not support extending this section to include export because the importing countries are likely to have their own requirements and New Zealand exporters should have the flexibility to meet these requirements. Export will not be prohibited if clause 7 of the Bill is not extended to include export. Previous convictions 171. Eleven percent of submissions raised concerns about whether individuals with previous drug convictions should be able to work in the medicinal cannabis industry. Of those submissions, 95 percent (including submissions from the public, industry and other organisations) supported these individuals being able to work in the cannabis industry. Only one percent of submissions that mentioned the issue were against these individuals being able to work in the cannabis industry Medicinal cannabis products are medicines and most are currently either controlled drugs or substances capable of producing a psychoactive effect. The Ministry considers that the requirements for issuing licences for medicines, controlled drugs and psychoactive substances are all relevant for determining the licensing requirements for medicinal cannabis products The licensing requirements are likely to be at least as strong as the Misuse of Drugs (Industrial Hemp) Regulations 2006, which are made under the Act. The Hemp Regulations prevent licence holders, directors and responsible people from having drug or dishonesty convictions In addition to these requirements, under the Psychoactive Substances Act the Psychoactive Substances Regulatory Authority must take into account whether the applicant has convictions under the Medicines or Psychoactive Substances Acts. It is likely that the licensing requirements for medicinal cannabis products will also prevent licence holders, directors and responsible people from having medicines and psychoactive substances convictions Neither the Misuse of Drugs Act, nor the Psychoactive Substances Act extend these requirements to all staff and it is unlikely that the fit and proper person test would be extended to all staff under the Medicinal Cannabis Scheme. A review of the Misuse of Drugs Act and penalties 176. Three percent of submissions specifically recommended changes to the penalties imposed by the Act An additional fourteen percent of submissions (22 submitters) recommended a full review of the Act Both a change to the penalties and a full review of the Act are outside the scope of the Bill. 19

Coversheet: Medicinal cannabis: 100 day action

Coversheet: Medicinal cannabis: 100 day action Coversheet: Medicinal cannabis: 100 day action Advising agencies Decision sought Proposing Ministers Ministry of Health Introduction of Misuse of Drugs Amendment Bill Hon Dr David Clark, Minister of Health

More information

3. Based on these principles, I propose a Misuse of Drugs Amendment Bill that will:

3. Based on these principles, I propose a Misuse of Drugs Amendment Bill that will: In Confidence Office of the Minister of Health Chair Cabinet Business Committee Medicinal cannabis: 100-Day Action Proposal 1. This paper seeks Cabinet policy approval for legislative changes that will

More information

Psychoactive Substances (Increasing Penalty for Supply and Distribution) Amendment Bill

Psychoactive Substances (Increasing Penalty for Supply and Distribution) Amendment Bill Psychoactive Substances (Increasing Penalty for Supply and Distribution) Amendment Bill 16 1 Report of the Justice Committee September 2018 Contents Recommendation... 2 About the bill as introduced...

More information

Cannabis Legalization and Regulation in British Columbia Discussion Paper

Cannabis Legalization and Regulation in British Columbia Discussion Paper Cannabis Legalization and Regulation in British Columbia Discussion Paper Introduction In 2015, the federal government committed to legalizing non-medical cannabis in Canada. On June 30, 2016, it established

More information

Australian and New Zealand College of Anaesthetists (ANZCA) Submission to Misuse of Drugs (Medicinal Cannabis) Amendment Bill Page 0

Australian and New Zealand College of Anaesthetists (ANZCA) Submission to Misuse of Drugs (Medicinal Cannabis) Amendment Bill Page 0 Page 0 Table of contents Page 1. Executive Summary 2 2. About ANZCA 3 3. About FPM 4 4. ANZCA response to the Misuse of Drugs (Medicinal Cannabis) Amendment Bill 5 4.1 ANZCA Position on medicinal cannabis

More information

January 19, Cannabis Legalization and Regulation Secretariat Address locator 0602E Health Canada Ottawa, Ontario K1A 0K9

January 19, Cannabis Legalization and Regulation Secretariat Address locator 0602E Health Canada Ottawa, Ontario K1A 0K9 January 19, 2018 Cannabis Legalization and Regulation Secretariat Address locator 0602E Health Canada Ottawa, Ontario K1A 0K9 By email: cannabis@canada.ca RE: Proposed Approach to the Regulation of Cannabis

More information

FACT SHEET PREPARED BY THE MINISTRY OF JUSTICE ON THE DANGEROUS DRUGS (AMENDMENT) ACT 2015 OVERVIEW 1. This Fact Sheet sets out the main changes that have been made to the Dangerous Drugs Act (the DDA

More information

Understanding the New Access to Cannabis for Medical Purposes Regulations

Understanding the New Access to Cannabis for Medical Purposes Regulations Understanding the New Access to Cannabis for Medical Purposes Regulations Health Canada August 2016 Table of Contents 1. Introduction 2. Health Canada's role 3. What it means for health care practitioners

More information

Criminal Justice (Psychoactive Substances) Bill Regulatory Impact Analysis

Criminal Justice (Psychoactive Substances) Bill Regulatory Impact Analysis Criminal Justice (Psychoactive Substances) Bill 2010 Regulatory Impact Analysis 1. Summary RIA Summary of Regulatory Impact Analysis (RIA) Department/Office: Department of Justice and Law Reform Stage:

More information

Regulatory Impact Statement. The International Convention on Standards of Training, Certification and Watchkeeping 1978

Regulatory Impact Statement. The International Convention on Standards of Training, Certification and Watchkeeping 1978 Regulatory Impact Statement Introducing a Blood Alcohol Limit for On-duty Seafarers The International Convention on Standards of Training, Certification and Watchkeeping 1978 Agency disclosure statement

More information

SECTION V: EMPLOYEES POLICY 5375 MEDICAL MARIJUANA, HEMP & CANNABIDIOL (CBD)

SECTION V: EMPLOYEES POLICY 5375 MEDICAL MARIJUANA, HEMP & CANNABIDIOL (CBD) Regardless of a student, employee, parent or any individual s status as a medical marijuana license holder, marijuana is not allowed on the premises of the district or in any school vehicle or in any personal

More information

Greens NSW Drug Regulation and Harm Minimisation Policy

Greens NSW Drug Regulation and Harm Minimisation Policy Greens NSW Drug Regulation and Harm Minimisation Policy Revised February 2015 Principles The NSW Greens believe: 1. Drug use has occurred throughout history and this is unlikely to change. Further, abuse

More information

Legalization, Regulation and Restriction of Access to Cannabis

Legalization, Regulation and Restriction of Access to Cannabis Legalization, Regulation and Restriction of Access to Cannabis Presentation to UNSM May 26th, 2017 Departments of Justice, Health and Wellness and Finance and Treasury Board Today Origin and Federal Context

More information

Yukon s Proposed Framework for. Legalized Cannabis 30 GRAMS MINIMUM AGE

Yukon s Proposed Framework for. Legalized Cannabis 30 GRAMS MINIMUM AGE Yukon s Proposed Framework for Legalized Cannabis 30 GRAMS x4 MINIMUM AGE Overview The Government of Yukon has begun developing a new act to regulate cannabis in response to federal legislation planned

More information

In Confidence. Office of the Associate Minister Health. Chair, Social Policy Committee. Regulation of smokeless tobacco and nicotine-delivery products

In Confidence. Office of the Associate Minister Health. Chair, Social Policy Committee. Regulation of smokeless tobacco and nicotine-delivery products In Confidence Office of the Associate Minister Health Chair, Social Policy Committee Regulation of smokeless tobacco and nicotine-delivery products Proposal 1 This paper seeks approval to prepare and issue

More information

Review of Controlled Drugs and Substances Act

Review of Controlled Drugs and Substances Act Review of Controlled Drugs and Substances Act Canadian Medical Association: Submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations A

More information

Amending Your Land Use Bylaw To Prepare For The Retail Sale Of Cannabis

Amending Your Land Use Bylaw To Prepare For The Retail Sale Of Cannabis 1 Amending Your Land Use Bylaw To Prepare For The Retail Sale Of Cannabis The Federal Government has proposed that by July 2018 non -medical cannabis will be legalized in Canada. Currently, cannabis possession

More information

Proposed Radiation Safety Regulations: Submission form

Proposed Radiation Safety Regulations: Submission form Proposed Radiation Safety Regulations: Submission form Making a submission This form is designed to assist submitters responding to the discussion points in Proposed Radiation Safety Regulations: A consultation

More information

OREGON MEDICAL MARIJUANA ACT

OREGON MEDICAL MARIJUANA ACT OREGON MEDICAL MARIJUANA ACT 475.300 Findings. The people of the state of Oregon hereby find that: (1) Patients and doctors have found marijuana to be an effective treatment for suffering caused by debilitating

More information

Legalization and Regulation of Recreational Cannabis PRESENTATION LPPANS NOVEMBER 22, 2017

Legalization and Regulation of Recreational Cannabis PRESENTATION LPPANS NOVEMBER 22, 2017 Legalization and Regulation of Recreational Cannabis PRESENTATION LPPANS NOVEMBER 22, 2017 2 2 Purpose for Today Review: Timeline Overview of Federal Legislation Consultation update Next Steps 3 Nova Scotia

More information

Proposed Excise Duty Framework for Cannabis Products

Proposed Excise Duty Framework for Cannabis Products Department of Finance Canada Proposed Excise Duty Framework for Cannabis Products 1. Introduction and Purpose The Government of Canada is committed to providing regulated and restricted access to cannabis,

More information

Establishment of a New Drug Code for Marihuana Extract. AGENCY: Drug Enforcement Administration, Department of Justice.

Establishment of a New Drug Code for Marihuana Extract. AGENCY: Drug Enforcement Administration, Department of Justice. This document is scheduled to be published in the Federal Register on 12/14/2016 and available online at https://federalregister.gov/d/2016-29941, and on FDsys.gov Billing Code 4410-09-P DEPARTMENT OF

More information

1. Introduction. 2. Role of PSI as Pharmacy Regulator

1. Introduction. 2. Role of PSI as Pharmacy Regulator 1. Introduction 1.1. I would like to begin by thanking the Committee for inviting the Pharmaceutical Society of Ireland here today to assist in the Committee s on-going scrutiny of the Cannabis for Medicinal

More information

78th OREGON LEGISLATIVE ASSEMBLY Regular Session. Senate Bill 964 SUMMARY

78th OREGON LEGISLATIVE ASSEMBLY Regular Session. Senate Bill 964 SUMMARY Sponsored by Senators BURDICK, KRUSE th OREGON LEGISLATIVE ASSEMBLY-- Regular Session Senate Bill SUMMARY The following summary is not prepared by the sponsors of the measure and is not a part of the body

More information

POISONS SCHEDULING. Monique Reyes Senior Pharmaceutical Officer Pharmaceutical Regulatory Unit NSW Ministry of Health

POISONS SCHEDULING. Monique Reyes Senior Pharmaceutical Officer Pharmaceutical Regulatory Unit NSW Ministry of Health POISONS SCHEDULING Monique Reyes Senior Pharmaceutical Officer Pharmaceutical Regulatory Unit NSW Ministry of Health Topics Schedules of the Poisons Standard (Cth) Poisons and Therapeutic Goods Act 1966

More information

I am pleased to highlight for this Honourable House and the public. that today the Government will be laying amendments to the

I am pleased to highlight for this Honourable House and the public. that today the Government will be laying amendments to the MINISTERIAL STATEMENT TO THE HOUSE OF ASSEMBLY BY THE HONOURABLE KIM N. WILSON, JP, MP MINISTER OF HEALTH UPDATES AND MODERNIZATION OF DRUG SCHEDULES 24 November 2017 Mr Speaker and Honourable Members,

More information

HRS Group UK Drug and Alcohol Policy

HRS Group UK Drug and Alcohol Policy HRS Group UK Drug and Alcohol Policy 1.0 Introduction The HRS Group UK Policy on Alcohol and Drugs is a fundamental part of the Company s strategy to safeguard the health, safety and welfare of all its

More information

An Overview of the Government of Canada s Approach to Legalize, Regulate and Restrict Access to Cannabis. February 2018

An Overview of the Government of Canada s Approach to Legalize, Regulate and Restrict Access to Cannabis. February 2018 An Overview of the Government of Canada s Approach to Legalize, Regulate and Restrict Access to Cannabis February 2018 I m here today to provide 1 2 3 Context for the Government of Canada s plan to legalize,

More information

MEMORANDUM. DATE: November 19, Senator Kohl-Welles. Kathleen Buchli, Counsel medical marijuana proposal

MEMORANDUM. DATE: November 19, Senator Kohl-Welles. Kathleen Buchli, Counsel medical marijuana proposal MEMORANDUM DATE: November 19, 2014 TO: Senator Kohl-Welles FROM: Kathleen Buchli, Counsel SUBJECT: 2015 medical marijuana proposal You requested an outline that describes your 2015 proposal that addresses

More information

An Overview of the Government of Canada s Approach to Legalize, Regulate and Restrict Access to Cannabis

An Overview of the Government of Canada s Approach to Legalize, Regulate and Restrict Access to Cannabis An Overview of the Government of Canada s Approach to Legalize, Regulate and Restrict Access to Cannabis I m here today to provide 1 2 3 Context for the Government of Canada s plan to legalize, regulate

More information

Medical Cannabis Comes to Maryland: What Finance Professionals Need to Know About this Budding Industry

Medical Cannabis Comes to Maryland: What Finance Professionals Need to Know About this Budding Industry Medical Cannabis Comes to Maryland: What Finance Professionals Need to Know About this Budding Industry *Views expressed are my own. Emily A. Burns* Attorney, Offit Kurman Roadmap: Key Terms Overview of

More information

Legalization of Cannabis- Overview

Legalization of Cannabis- Overview Legalization of Cannabis- Overview Presentation to Regional Council Education Workshop February 15, 2018 Joy Hulton, Regional Solicitor 1 Overview Background Federal Cannabis Framework Provincial Legislation

More information

SB 1262 (Correa): Medical Marijuana Regulation and Local Control Informational Webinar February 25, 2014

SB 1262 (Correa): Medical Marijuana Regulation and Local Control Informational Webinar February 25, 2014 SB 1262 (Correa): Medical Marijuana Regulation and Local Control Informational Webinar February 25, 2014 Webinar Moderator Bismarck Obando Public Affairs Director, League of California Cities Agenda Introduction,

More information

MICHIGAN MEDICAL MARIJUANA REGULATION: From Home Remedy to Criminalization. to State Regulated Industry. March 22, Stephen K.

MICHIGAN MEDICAL MARIJUANA REGULATION: From Home Remedy to Criminalization. to State Regulated Industry. March 22, Stephen K. MICHIGAN MEDICAL MARIJUANA REGULATION: From Home Remedy to Criminalization to State Regulated Industry Presentation to the Michigan Municipal League Capital Conference March 22, 2017 Stephen K. Postema

More information

Impact Summary: Therapeutic Products Bill Personal Import of Medicine by mail/courier

Impact Summary: Therapeutic Products Bill Personal Import of Medicine by mail/courier Impact Summary: Therapeutic Products Bill Personal Import of Medicine by mail/courier Section 1: General information Purpose The Ministry of Health is solely responsible for the analysis and advice set

More information

Act on Narcotic Drugs and Psychotropic Substances and Precursors thereof

Act on Narcotic Drugs and Psychotropic Substances and Precursors thereof Issuer: Riigikogu Type: act In force from: 13.05.2016 In force until: 22.11.2018 Translation published: 06.05.2016 Act on Narcotic Drugs and Psychotropic Substances and Precursors thereof Amended by the

More information

Submission to the Misuse of Drugs Amendment Bill September Society and its Role and Functions. 29 September 2010

Submission to the Misuse of Drugs Amendment Bill September Society and its Role and Functions. 29 September 2010 PHARMACY HOUSE 124 DIXON STREET PO BOX 11 640 WELLINGTON NEW ZEALAND TELEPHONE 04 802 0030 FAX 04 382 9297 EMAIL p.society@psnz.org.nz WEBSITE www.psnz.org.nz 29 September 2010 Clerk of the Health Committee

More information

STAFF REPORT City of Lancaster NB 2

STAFF REPORT City of Lancaster NB 2 STAFF REPORT City of Lancaster NB 2 12/13/16 MVB Date: December 13, 2016 To: From: Subject: Mayor Parris and City Council Members Mark V. Bozigian, City Manager Allison E. Burns, City Attorney Ordinance

More information

Legalization of Cannabis: The Way Forward

Legalization of Cannabis: The Way Forward Percent 2018/05/03 Legalization of Cannabis: The Way Forward W. O. McCormick Academic Day Hon. A. Anne McLellan, PC, OC, AOE Friday, April 27 2018 Current Context 40 Past year cannabis use, by age group,

More information

Oregon State University Guidance on Cannabis Research, Teaching, and Outreach Activities

Oregon State University Guidance on Cannabis Research, Teaching, and Outreach Activities Oregon State University Guidance on Cannabis Research, Teaching, and Outreach Activities For faculty, staff, and students involved in research and extension The purpose of this document is to provide Oregon

More information

MARIJUANA LEGALIZATION. INITIATIVE STATUTE.

MARIJUANA LEGALIZATION. INITIATIVE STATUTE. PROPOSITION MARIJUANA LEGALIZATION. OFFICIAL TITLE AND SUMMARY Legalizes marijuana under state law, for use by adults 21 or older. Designates state agencies to license and regulate marijuana industry.

More information

ORDINANCE NO

ORDINANCE NO ORDINANCE NO. 01-2017 AN ORDINANCE OF THE CITY COUNCIL OF THE CITY OF SEMINOLE, FLORIDA, REGARDING MEDICAL CANNABIS; IMPOSING A TEMPORARY MORATORIUM ON THE SALE OF MEDICAL CANNABIS AND ON THE ESTABLISHMENT

More information

CHAPTER Committee Substitute for Committee Substitute for Senate Bill No. 1030

CHAPTER Committee Substitute for Committee Substitute for Senate Bill No. 1030 CHAPTER 2014-157 Committee Substitute for Committee Substitute for Senate Bill No. 1030 An act relating to cannabis; providing a short title; creating s. 381.986, F.S.; defining terms; authorizing specified

More information

Medicinal cannabis. What is medicinal cannabis? What are cannabinoids? The endocannabinoid system

Medicinal cannabis. What is medicinal cannabis? What are cannabinoids? The endocannabinoid system Medicinal cannabis What is medicinal cannabis? Broadly speaking, medicinal cannabis is cannabis prescribed to relieve the symptoms of a medical condition, such as epilepsy. It is important to make the

More information

Cannabis Legalization August 22, Ministry of Attorney General Ministry of Finance

Cannabis Legalization August 22, Ministry of Attorney General Ministry of Finance Cannabis Legalization August 22, 2018 Ministry of Attorney General Ministry of Finance Federal Cannabis Legalization and Regulation The federal Cannabis Act received Royal Assent on June 21, 2018 and will

More information

Industrial Hemp. What is industrial hemp? Is industrial hemp the same as marihuana? Why has hemp been illegal to cultivate in Canada in the past?

Industrial Hemp. What is industrial hemp? Is industrial hemp the same as marihuana? Why has hemp been illegal to cultivate in Canada in the past? Industrial Hemp What is industrial hemp? Industrial Hemp is a tall, leafy plant with a strong fibrous stalk. Although Industrial Hemp varieties are members of the Cannabis plant family, they contain very

More information

ENROLLED 2014 Legislature CS for CS for SB 1030, 1st Engrossed

ENROLLED 2014 Legislature CS for CS for SB 1030, 1st Engrossed 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 An act relating to cannabis; providing a short title; creating s. 381.986, F.S.; defining terms; authorizing specified physicians

More information

The Court Order read out by Deputy Chief Justice Zondo is as follows:

The Court Order read out by Deputy Chief Justice Zondo is as follows: Cancer Association of South Africa (CANSA) Fact Sheet and Position Statement on Cannabis in South Africa Introduction Cannabis is a drug that comes from Indian hemp plants such as Cannabis sativa and Cannabis

More information

LEGAL ASPECTS of MEDICAL MARIJUANA Florida Nurse Practitioner Network Annual Conference September 17, 2018

LEGAL ASPECTS of MEDICAL MARIJUANA Florida Nurse Practitioner Network Annual Conference September 17, 2018 LEGAL ASPECTS of MEDICAL MARIJUANA Florida Nurse Practitioner Network Annual Conference September 17, 2018 DISCLAIMER The material presented is general legal information and is not legal advice. Specific

More information

REQUEST FOR DECISION Subject: Bylaw 420 Land Use Bylaw Amending Bylaw Cannabis and Cannabis Related Business Definitions

REQUEST FOR DECISION Subject: Bylaw 420 Land Use Bylaw Amending Bylaw Cannabis and Cannabis Related Business Definitions REQUEST FOR DECISION Subject: Bylaw 420 Land Use Bylaw Amending Bylaw Cannabis and Cannabis Related Business Definitions Presented to: Council Date: February 26th, 2018 Submitted by: Randall McKay Director,

More information

Submission to the Senate Community Affairs Legislation Committee inquiry into the Therapeutic Goods Amendment (2016 Measures No.

Submission to the Senate Community Affairs Legislation Committee inquiry into the Therapeutic Goods Amendment (2016 Measures No. Submission to the Senate Community Affairs Legislation Committee inquiry into the Therapeutic Goods Amendment (2016 Measures No. 1) Bill 2016 Submitted by: Submitted electronically to: Complementary Medicines

More information

Provincially-Licensed Cannabis Retail Stores in Toronto

Provincially-Licensed Cannabis Retail Stores in Toronto CC1.4 REPORT FOR ACTION Provincially-Licensed Cannabis Retail Stores in Toronto Date: December 6, 2018 To: City Council From: City Manager Wards: All SUMMARY Provincially-licensed private cannabis retail

More information

Proposal 18-1: Marijuana Legalization

Proposal 18-1: Marijuana Legalization Proposal 18-1: Marijuana Legalization November 2018 Statewide Ballot Issues Webinar - October 16, 2018 Tim Michling, Research Associate Citizens Research Council of Michigan 2 Access our analyses, official

More information

Submission - The Substance Addiction Compulsory Assessment and Treatment (SACAT) Bill

Submission - The Substance Addiction Compulsory Assessment and Treatment (SACAT) Bill Submission - The Substance Addiction Compulsory Assessment and Treatment (SACAT) Bill Submission to: Health Select Committee April 2016 Submission from: Addiction Practitioners Association Aotearoa New

More information

Torkin Manes LegalPoint

Torkin Manes LegalPoint LegalPoint JULY 2017 Marijuana and the Canadian Workplace The possession, use and sale of marijuana in Canada presently remains unlawful under the Controlled Drugs and Substances Act, but its use for medical

More information

Case scenarios: Patient Group Directions

Case scenarios: Patient Group Directions Putting NICE guidance into practice Case scenarios: Patient Group Directions Implementing the NICE guidance on Patient Group Directions (MPG2) Published: March 2014 [updated March 2017] These case scenarios

More information

Cannabis Legalization Proposed Bylaws

Cannabis Legalization Proposed Bylaws 2018 April 03 Page 1 of 7 EXECUTIVE SUMMARY On 2017 April 13, the Government of Canada introduced Bill C-45, An Act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal

More information

PIC/S GUIDANCE ON CLASSIFICATION OF GMP DEFICIENCIES

PIC/S GUIDANCE ON CLASSIFICATION OF GMP DEFICIENCIES PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 040-1 3 Appendices 1 January 2019 PIC/S GUIDANCE ON CLASSIFICATION OF GMP DEFICIENCIES PIC/S January 2019 Reproduction

More information

Bill C-51 and Natural Health Products - The Facts

Bill C-51 and Natural Health Products - The Facts Bill C-51 and Natural Health Products - The Facts 1. How will Bill C-51 change the way natural health products are regulated? Bill C-51 will not affect the way that natural health products are regulated

More information

2018 Farm Bill to Lift Federal Prohibition on Hemp Production, but State Laws May Restrict Certain Activities

2018 Farm Bill to Lift Federal Prohibition on Hemp Production, but State Laws May Restrict Certain Activities Debevoise Update D&P 2018 Farm Bill to Lift Federal Prohibition on Hemp Production, but State Laws May Restrict Certain Activities December 13, 2018 Earlier this week, the U.S. House of Representatives

More information

MOTION FOR A RESOLUTION

MOTION FOR A RESOLUTION European Parliament 2014-2019 Committee on the Environment, Public Health and Food Safety 2.10.2018 2018/2775(RSP) MOTION FOR A RESOLUTION further to Question for Oral Answer B8-0000/2018 pursuant to Rule

More information

REQUEST FOR DECISION Subject: Bylaw 420 Land Use Bylaw Amending Bylaw Cannabis and Cannabis Related Businesses Definitions

REQUEST FOR DECISION Subject: Bylaw 420 Land Use Bylaw Amending Bylaw Cannabis and Cannabis Related Businesses Definitions REQUEST FOR DECISION Subject: Bylaw 420 Land Use Bylaw Amending Bylaw Cannabis and Cannabis Related Definitions Presented to: Council Submitted by: Randall McKay Director, Planning and Development Dave

More information

LEGALIZED AND MEDICAL MARIJUANA IN THE WORKPLACE

LEGALIZED AND MEDICAL MARIJUANA IN THE WORKPLACE LEGALIZED AND MEDICAL MARIJUANA IN THE WORKPLACE Saskatchewan Industrial & Mining Suppliers Association Inc. November 23, 2017 Kevin Wilson, Q.C. 1 WEED AT WORK Saskatchewan Industrial & Mining Suppliers

More information

Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients

Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients Pharmaceutical Society of Ireland Version 3 October 2017 Updates made following the enactment

More information

April 7, You have asked me to prepare an opinion letter regarding the legal status of cannabidiol ( CBD ).

April 7, You have asked me to prepare an opinion letter regarding the legal status of cannabidiol ( CBD ). Palmetto Synergistic Research, LLC d/b/a Palmetto Harmony Attn. Janel Ralph 216 Labonte Street, Unit B Conway, SC 29526 April 7, 2016 Re: Cannabidiol opinion letter Dear Ms. Ralph: You have asked me to

More information

Office of University Counsel and Secretary of the Board of Regents

Office of University Counsel and Secretary of the Board of Regents To: From: University of Colorado Research Faculty President Bruce D. Benson University Counsel Patrick T. O Rourke Date: March 11, 2014 Re: Legality of Marijuana Research Colorado is one of twenty states

More information

Cannabis Regulation in Canada:

Cannabis Regulation in Canada: Cannabis Regulation in Canada: Where We Came From, Where We Are and What s Coming Next Jonathan Sherman Cassels Brock & Blackwell LLP Sherri Altshuler Aird & Berlis LLP Canada, In Brief Right Now... Legal

More information

Explanatory Memorandum to accompany the following subordinate legislation-

Explanatory Memorandum to accompany the following subordinate legislation- Explanatory Memorandum to accompany the following subordinate legislation- 1. Care Standards Act 2000 (Extension of the Application of Part 2 to Private Dental Practices) (Wales) Regulations 2017, 2. Private

More information

O vercom ing Banking Obstacles for Marijuana-Related Businesses. Lori Jean Partner, Krieg DeVault LLP

O vercom ing Banking Obstacles for Marijuana-Related Businesses. Lori Jean Partner, Krieg DeVault LLP O vercom ing Banking Obstacles for Marijuana-Related Businesses Lori Jean Partner, Krieg DeVault LLP The Opportunity Legal Marijuana Sales in the U.S. Expected to reach $50B annually by 2026 CBD market

More information

Navigating the Rapidly Changing World of Marijuana and the Workplace. January 16, 2018

Navigating the Rapidly Changing World of Marijuana and the Workplace. January 16, 2018 Legal Update Navigating the Rapidly Changing World of Marijuana and the Workplace January 16, 2018 Within the last few years, 28 states and the District of Columbia have legalized marijuana in varying

More information

Maine s Medical Marijuana Law. 40 th Annual ASMAC Fall Conference Ritz Carlton Lake Tahoe October 26, 2014

Maine s Medical Marijuana Law. 40 th Annual ASMAC Fall Conference Ritz Carlton Lake Tahoe October 26, 2014 Maine s Medical Marijuana Law 40 th Annual ASMAC Fall Conference Ritz Carlton Lake Tahoe October 26, 2014 Medical Marijuana Laws Alaska (1998) Arizona (1996, 2010) California (1996) Colorado (2000) Delaware

More information

THE RESPONSIBLE PHARMACIST REGULATIONS

THE RESPONSIBLE PHARMACIST REGULATIONS THE RESPONSIBLE PHARMACIST REGULATIONS A SUMMARY OF THE RESPONSES TO PUBLIC CONSULTATION ON PROPOSALS FOR THE CONTENT OF THE REGULATIONS DH INFORMATION READER BOX Policy HR / Workforce Management Planning

More information

Alcohol & Drug Practice

Alcohol & Drug Practice Alcohol & Drug Practice Vice-President, Health & Safety June 1, 2011 Purpose Cenovus recognizes that the use of alcohol and drugs can adversely affect job performance, the work environment and the safety

More information

Review of Medicines Act 1968: informal consultation on issues relating to the PLR regime and homeopathy

Review of Medicines Act 1968: informal consultation on issues relating to the PLR regime and homeopathy Review of Medicines Act 1968: informal consultation on issues relating to the PLR regime and homeopathy Introduction 1. The consolidation and review of the UK medicines legislation (including the Medicines

More information

City of Coral Gables Planning and Zoning Staff Recommendation

City of Coral Gables Planning and Zoning Staff Recommendation City of Coral Gables Planning and Zoning Staff Recommendation Applicant: Application: Public Hearing - Dates/Time/ Location: City of Coral Gables Zoning Code Text Amendment- Article 8, Definitions, Article

More information

Policy / Drug and Alcohol-Free Workshops

Policy / Drug and Alcohol-Free Workshops Policy 4118.235/4218.235 Drug and Alcohol-Free Workshops DATE: February 13, 2017 PREVIOUS ITEM: None ENCLOSURES: CABE s Suggested Policy 4118.235/4218.235 CABE s July 15, 2016 Policy Update REASON: To

More information

James Donaldson CEO and Executive Director

James Donaldson CEO and Executive Director Welcome! James Donaldson CEO and Executive Director Dr. Natasha Ryz Chief Science Officer, Zenabis Cannabis 101 Introduction to Cannabis Plant Cannabis is a genus of flowering plants within the family

More information

MEDICINES, MEDICAL DEVICES, TREATMENTS AND HEALTH

MEDICINES, MEDICAL DEVICES, TREATMENTS AND HEALTH 11 MEDICINES, MEDICAL DEVICES, TREATMENTS AND HEALTH Background The rules in this section are designed to ensure that advertisements that include health claims (please see Section 13 for health claims

More information

Consultation: Discontinuing pre-market evaluation of Herbal Component Names (HCNs)

Consultation: Discontinuing pre-market evaluation of Herbal Component Names (HCNs) Complementary Medicines Australia submission to the Therapeutic Goods Administration Consultation: Consultation: Discontinuing pre-market evaluation of Herbal Component Names (HCNs) 12 January 2018 To:

More information

Changes to Australian Government Hearing Services Program and Voucher scheme

Changes to Australian Government Hearing Services Program and Voucher scheme Changes to Australian Government Hearing Services Program and Voucher scheme The Commonwealth Department of Health has published a report on its investigation into the future of the Hearing Services Program,

More information

Cannabis Legalization

Cannabis Legalization Cannabis Legalization Meeting with Education Stakeholders October 26, 2018 Agenda 1. Welcome and Introductions (EDU) 2. Overview of Federal and Provincial cannabis legislation (MAG) 3. Overview of Licence

More information

2. The inclusion of public health focused restrictions around the sale and supply of these products.

2. The inclusion of public health focused restrictions around the sale and supply of these products. 1 May 2013 Committee Secretariat Health Select Committee Parliament Buildings Wellington Submission on the Psychoactive Substances Bill (RPH) serves the Greater Wellington region, through its three District

More information

About this guidance. Introduction. When there are no children on roll

About this guidance. Introduction. When there are no children on roll The process and guidance for inspecting childminders and childcare settings with no children on roll or no children present at the time of the inspection About this guidance The aim of this guidance is

More information

The doobies and don ts Legalized and medical marijuana in the workplace

The doobies and don ts Legalized and medical marijuana in the workplace The doobies and don ts Legalized and medical marijuana in the workplace Timothy D. Mitchell, Partner Rebecca Silverberg, Associate March 15, 2018 Agenda 1. Overview of marijuana legalization 2. Effects

More information

Dear Minister Farnworth

Dear Minister Farnworth Attn: Cannabis Legalization and Regulation Secretariat November 1, 2018 Ministry of Public Safety and Solicitor General File: 4912 PO Box 9285, Stn Prov Govt Victoria BC V8W 9J7 Via email: cannabis.secretariat@gov.bc.ca

More information

QUESTIONS AND ANSWERS

QUESTIONS AND ANSWERS QUESTIONS AND ANSWERS LEGISLATION When will the changes come into force? The Government hopes to have the bill passed into law before the end of this parliamentary term. It s anticipated that most changes

More information

Hamilton City Council BYLAWS HAMILTON ALCOHOL CONTROL BYLAW 2015

Hamilton City Council BYLAWS HAMILTON ALCOHOL CONTROL BYLAW 2015 Approved By: Council Date Adopted : 11 August 2010 Date Amended: 16 December 2015 Date Amendment came into force: 20 January 2016 Amendments: Update to include changes to Legislation, Style of bylaw updated

More information

Explanatory Notes Relating to Regulatory and Legislative Proposals Relating to the Taxation of Cannabis

Explanatory Notes Relating to Regulatory and Legislative Proposals Relating to the Taxation of Cannabis Explanatory Notes Relating to Regulatory and Legislative Proposals Relating to the Taxation of Cannabis Published by The Honourable William Francis Morneau, P.C., M.P. Minister of Finance September 2018

More information

Human Resources SHELL IN CANADA ALCOHOL AND DRUG POLICY

Human Resources SHELL IN CANADA ALCOHOL AND DRUG POLICY Human Resources SHELL IN CANADA ALCOHOL AND DRUG POLICY January 2015 OVERVIEW Objective and Principles The objective of Shell in Canada s Alcohol and Drug Policy is to provide a framework for dealing with

More information

Written Brief to the Standing Committee on Health

Written Brief to the Standing Committee on Health Canadian Association of Chiefs of Police Association canadienne des chefs de police Written Brief to the Standing Committee on Health C-45 - An Act respecting cannabis and to amend the Controlled Drugs

More information

Scottish Health Action on Alcohol Problems. Alcohol (Licensing, Public health and Criminal Justice) (Scotland) Bill

Scottish Health Action on Alcohol Problems. Alcohol (Licensing, Public health and Criminal Justice) (Scotland) Bill Scottish Health Action on Alcohol Problems Alcohol (Licensing, Public health and Criminal Justice) (Scotland) Bill This submission comes from Scottish Health Action on Alcohol Problems (SHAAP). SHAAP is

More information

Are We All Going to Pot?: Legal Issues Arising from Cannabis-Industry Growth The Canadian Perspective

Are We All Going to Pot?: Legal Issues Arising from Cannabis-Industry Growth The Canadian Perspective Are We All Going to Pot?: Legal Issues Arising from Cannabis-Industry Growth The Canadian Perspective John A. Myers and Colin B. Findlay SCG Legal Annual General Meeting September 16, 2016 Boston Licensed

More information

Marijuana Legalization Update

Marijuana Legalization Update Marijuana Legalization Update PJ McCann, Esq. Deputy General Counsel February 14, 2018 1 Context Many moving parts in Cannabis Control Commission (CNB) regulatory process Information and recommendations

More information

Alcohol, Tobacco and Other Drugs Minimum Standard. April 2015

Alcohol, Tobacco and Other Drugs Minimum Standard. April 2015 Alcohol, Tobacco and Other Drugs Minimum Standard April 2015 Contents 1 Executive Summary... 2 2 More Information... 2 3 Using this Standard... 2 4 Standard Provisions... 2 4.1 Legislative Requirements...

More information

SENATE BILL No. 676 AMENDED IN SENATE APRIL 28, 2011 AMENDED IN SENATE MARCH 31, Introduced by Senator Leno.

SENATE BILL No. 676 AMENDED IN SENATE APRIL 28, 2011 AMENDED IN SENATE MARCH 31, Introduced by Senator Leno. AMENDED IN SENATE APRIL, 0 AMENDED IN SENATE MARCH, 0 SENATE BILL No. Introduced by Senator Leno February, 0 An act to add Division (commencing with Section 000) to the Food and Agricultural Code, and

More information

Australian Medicinal Cannabis Pricing Analysis

Australian Medicinal Cannabis Pricing Analysis Australian Medicinal Cannabis Pricing Analysis Q3 2018 cannabis access clinics » Entry level product prices fall by close to 50% over 12 months» Number of legal products available up threefold» Pharmacy

More information

SUBJECT: Cannabis legislation and implications for the City of Burlington

SUBJECT: Cannabis legislation and implications for the City of Burlington Page 1 of Report CM-11-17 SUBJECT: Cannabis legislation and implications for the City of Burlington TO: FROM: Committee of the Whole City Manager's Office Report Number: CM-11-17 Wards Affected: All File

More information

ORDINANCE NO SECTION 1. The Board of Supervisors makes the following findings in support of this ordinance:

ORDINANCE NO SECTION 1. The Board of Supervisors makes the following findings in support of this ordinance: ORDINANCE NO. 2017- AN ORDINANCE AMENDING TITLE 17 OF THE ALAMEDA COUNTY GENERAL ORDINANCE CODE TO CONDITIONALLY PERMIT MEDICAL CANNABIS DISPENSARIES IN SPECIFIED DISTRICTS WITHIN THE UNINCORPORATED AREA

More information

Drugs, Alcohol and Substance Misuse Policy

Drugs, Alcohol and Substance Misuse Policy 1. Introduction 2. Scope of Policy 3. Overview and Policy Detail 4. Education, Intervention and Referral 5. Disruptive or Dangerous Behaviour 6. College Accommodation 7. Consequences 8. Status of Policy

More information

Gisborne District Council Alcohol Control Bylaw 2015

Gisborne District Council Alcohol Control Bylaw 2015 APPENDIX 2 Gisborne District Council Alcohol Control Bylaw 2015 Statement of Proposal May 2015 A569837 Page 1 Introduction This is a Statement of Proposal prepared in accordance with section 83(1)(a) of

More information